BioLineRx Ltd. Press Releases

BLRX 
$1.72
*  
0.02
1.15%
Get BLRX Alerts
*Delayed - data as of Dec. 18, 2014 15:22 ET  -  Find a broker to begin trading BLRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    BLRX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates
12/16/2014 7:00:00 AM - Business Wire
▼-4.44 % Price Change since this news event. The Volume Ratio is 7.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform
12/12/2014 7:00:00 AM - Business Wire
▼-6.01 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference
12/8/2014 7:00:00 AM - Business Wire
▼-6.52 % Price Change since this news event. The Volume Ratio is 13.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx Reports Third Quarter 2014 Financial Results
11/10/2014 7:00:00 AM - Business Wire
▲19.44 % Price Change since this news event. The Volume Ratio is 1.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment
11/5/2014 7:00:00 AM - Business Wire
▲25.55 % Price Change since this news event. The Volume Ratio is 1.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx to Report Third Quarter 2014 Results on November 10, 2014
11/3/2014 8:00:00 AM - Business Wire
▲23.74 % Price Change since this news event. The Volume Ratio is 2.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile
11/3/2014 7:00:00 AM - Business Wire
▲23.74 % Price Change since this news event. The Volume Ratio is 2.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
10/31/2014 7:00:00 AM - Business Wire
▲22.86 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day